Mammalian mismatch repair (MMR) plays a prominent role in genomic stability and toxicity induced by some DNA damaging agents. Advance in the appreciation of regulation mechanisms of the key MMR protein hMSH2 would certainly lead to valuable information on its role and to a better understanding of MMR system dysfunctions with respect to their consequences in cells. We have previously reported that, in myeloid leukemic U937 cell line, the expression of hMSH2 MMR protein is regulated by protein kinase C (PKC) activity. Here we show that the increase of protein level following PKC activation by phorbol ester (TPA) treatment parallels that of hMSH2 mRNA. Our results support the view that the hMSH2 gene is prone to transcriptional regulation upon TPA induction, and that AP-1 is a factor implicated in the transactivation. When losing the AP-1-dependent hMSH2 promoter activity, either by mutating the AP-1 binding sites of the hMSH2 promoter or by using a dominant negative c-Jun factor, the hMSH2 overexpression induced by TPA is abolished both in vitro and in vivo. Thus the control of hMSH2 expression by PKC appears to be dependent, at least partially, on an up-regulation mediated by AP-1 transactivation.
INTRODUCTION
DNA mismatch repair (MMR) has long been known to be involved in two important cellular processes: (i) the repair of mismatches generated by misincorporation of nucleotides during DNA replication and (ii) the processing of recombination intermediates (reviewed in 1,2). Mammalian MMR system functions as a combination of at least ®ve proteins that recognise mismatches and repair DNA via excision and replacement with the correct nucleotide (for reviews see 2±4). Repair is initiated by either one of two heterodimers, both including the hMSH2 protein. The hMSH2-hMSH6 (hMutSa) and the hMSH2-hMSH3 (hMutSb) complexes differ on their recognition speci®city. The former is directed on base±base substitution or small loops, while the latter binds mainly insertion±deletion of a larger number of nucleotides. The recognition complex bound to DNA recruits hMutLa, a heterodimer of hMLH1 and hPMS2, to perform the repair reaction.
Loss of MMR activity led to a mutator phenotype, consisting of a high mutation rate and an associated instability of genomic microsatellite sequences (MSI). Inactivation of the repair pathway is associated with cancer development, as illustrated by the inherited familial cancer syndrome of hereditary non-polyposis colon cancers (HNPCC) (5, 6) . Additionally, sporadic malignancies of gastrointestinal, gynaecological and genitourinary tracts are in part attributable to defective repair proteins (7) . In addition to the MSI+ phenotype, de®ciency in MMR activity leads to different phenotype (8) , such as the resistance to genotoxics, exempli®ed by the mechanism of tolerance to methylating agents (9) , or conversely, sensitivity to topoisomerase inhibitors via an indirect mechanism (10) .
Alterations of the MMR machinery are mainly documented as point mutations throughout the coding sequence of the components of the MMR system (6) for the most part in the hMSH2 and hMLH1 genes (11) . Despite the extensive biochemical and genetic studies, only limited information is available concerning the regulation of the MMR repair system. Non-mutational events can also be responsible for the variation of the MMR capacity. Treatment of cells with alkylating agents leads to an increase of the nuclear level of hMSH2 and hMSH6, and thus the binding activity, due to translocation of the proteins from cytoplasm (12) . Posttranslational modi®cation has also been described to take place following an in vivo phosphorylation of the hMuta complex, resulting in an improved capability of mismatch binding (13) . Phosphorylation is mediated in vitro by casein kinase II (CKII) and protein kinase C (PKC). Moreover, MMR can be modulated by changes in MMR gene expression. In methotrexate-resistant human cells, a gene ampli®cation of hMSH3 leads to an overproduction of the corresponding protein related to the depletion of the hMutSa complex, and thus to a partial mutator phenotype (14, 15) . Conversely, an epigenetic process marked by promoter region hypermethylation is associated with transcription loss of the hMLH1 gene (16) . Likewise the hMSH6 promoter can also be silenced by cytosine methylation (17) . And the identi®cation of two elements controlling the transcriptional activity of hMLH1 has been mentioned elsewhere (18 transcriptional regulation concerns the hMSH2 gene upon P53 activation (19, 20) . Recently, we initiated a study intending to identify internal or external signals that would affect the MMR expression and/ or function (21) . We found that PKC stimulation was responsible for increased expression and activity of proteins belonging to the MMR system in the U937 leukaemia cells after phorbol-ester treatment. In addition, increase in hMSH2 expression was inhibited by PKC antagonists, and our results suggested that activation of PKC isoforms by phorbol esters or DAG were able to modulate MMR activity.
In this study, we focused on further characterising the mechanism that sustains the increasing of hMSH2 expression. We brought here evidence that phorbol-ester-induced PKC stimulation favoured an induction of the hMSH2 gene transcription. Treatment of the cells with tetradecanoylphorbol-13-acetate (TPA) speci®cally increases the amount of hMSH2 mRNA. We carried out a functional analysis of the hMSH2 promoter region, in vitro and in vivo, demonstrating a direct participation of the Activator Protein-1 (AP-1) c-Jun factor in the up-regulation. We highlight here the existence of a cascade of positive regulation that occurs by successive activations of PKC, AP-1 transcription factor, hMSH2 gene expression and consequently MMR function. We hypothesise that increased hMSH2 expression could play a protective role in the terminal differentiation pathway in the leukaemia model.
MATERIALS AND METHODS

Cell lines and chemicals
HeLa cells were obtained from the European Molecular Biology Laboratory (Heidelberg, Germany). Monocytic U937 cells were from the ATCC (Rockville, MD). U937 cells, stably transfected with a dominant negative of c-Jun (22) or with the empty vector, were kindly provided by Dr K. Nakaya (Showa University, Tokyo, Japan). Cells were cultured in RPMI 1640 media supplemented with 10% fetal calf serum, 2 mM L-glutamine, 100 mg/ml streptomycin and 200 U/ml of penicillin. For stable transfectants, 200 mg/ml of G418 are added to the culture medium. Cells were maintained at 37°C in a humidi®ed atmosphere with 5% CO 2 , and were routinely tested for mycoplasmal infection. Treatment with TPA (50 nM, except when noti®ed) were done on serum-starved cells. All the chemicals were purchased from Sigma (St Quentin-Fallavier, France).
Semi-quantitative reverse transcription
Total RNA was extracted from cell cultures using TRIZOL reagent (Gibco BRL) and resuspended in H 2 O-DEPC. Quantity and quality of RNAs were evaluated by capillar electrophoresis on Agilent 2000 Bioanalyser (Agilent Technologies, Massy, France).
RT±PCR experiments were realised with the`Access RT±PCR system' kit (Promega, Madison, WI) to amplify fragments of mRNA of hMSH2 (450 bp), of the human b2 microglobuline (HB2, 167 bp) and the Escherichia coli kanamycin resistance gene (323 bp), using three sets of oligonucleotides. Sequences were the following: for hMSH2, 5¢-TTGGCATATAAGGCTTCTCCTGGC-3¢ and 5¢-TGC-AACCTGATTCTCCATTTCTGG-3¢; for HB2, 5¢-CATCC-AGCGTACTCCAAAGA-3¢ and 5¢-GACAAGTCTGAATG-CTCCAC-3¢; for the prokaryotic gene, 5¢-GCCATTCTCAC-CGGATTCAGTCGTC-3¢ and 5¢-AGCCGCCGTCCCGTC-AAGTCAG-3¢. Reactions consisted of co-ampli®cation of both the target RNA and the standard prokaryotic RNA in the same tube, in a ®nal volume of 75 ml containing 2.35 pg of control RNA, 2.25 mg of total RNA, 1.5 mM of the two corresponding sets of primers, 20 mCi of [a-32 P]dCTP (ICN, 3000 Ci/mmol) added to the other components of the kit. During completion of the cDNA synthesis, samplings of 5 ml were brought out at cycles 15, 20, 25, 30, 35 , for electrophoresis analysis on 5% polyacrylamide gel. Reaction products were detected and quanti®ed on a PhosphorImager (Storm System, Molecular Dynamics). The standard prokaryotic molecule did not interfere with the target. Signal from the bacterial exogenous control template coampli®ed in the same RT±PCR reaction served to normalise and to compare the hMSH2 sample data.
Western blot analysis
Total cell extracts were prepared from 2 Q 10 7 cells following the method described by Andrews and Faller (23) . After separation of the proteins (30 mg) on a 8% SDS±polyacryla-mide gel and transfer onto PVDF membrane (Hybond-P, Amersham Pharmacia Biotech), immunoblotting was performed using mouse monoclonal hMSH2 antibody (1 mg/ml, cloneG219-1129, Pharmingen). Mouse monoclonal PCNA antibody (clone PC10, Dako) was used as a loading control. After washing the blots, horseradish peroxidaseconjugated anti-mouse antibody was added to perform a chemoluminescent detection using the Super Signal kit (Pierce).
Electrophoretic mobility shift assay (EMSA)
Protein extracts used in EMSA were the same as described above. Substrates were duplex 32 P-labeled oligonucleotides. Sequences of the oligonucleotide used in the mismatch band shift experiments have been published (24) . Top strand sequences of the oligonucleotides used in the AP-1 band shift experiments are: AP-1/Coll., 5¢-ACACACGCTGA-CTCAGCATAAGCC-; AP-1/612, 5¢-CGAATGAGTGAAT-CATCAACGAGT-; 612mut, 5¢-CGAATGAGTTAACC-ATCAACGAGT-; 291mut, 5¢-CTTGCAGCTTAAGAAA-CACAGAAA-. A random 34mer was used as non-speci®c oligonucleotide. Band shift assays were performed as previously reported (25) . Brie¯y, extracts (30 mg) were incubated for 5 min at room temperature with 2 pmol of non-radioactive duplex in 15 ml of reaction mixture (25 mM HEPES±KOH pH 8.0, 0.5 mM EDTA, 1 mM dithiothreitol, 50 mM KCl, 50 mg/ml BSA, 5% glycerol). Incubation with the added radiolabeled oligonucleotide (20 fmol) continued for 20 min. Products of the reaction were separated on 6% polyacrylamide gels, and detected on the PhosphorImager (Storm System, Molecular Dynamics). When testing the effect of c-Jun antibody (rabbit polyclonal antibody, clone sc-44, Santa Cruz Biotechnology, CA) on the mobility complex, 0.5 mg of the antibody was added to the extracts prior to the radiolabeled oligonucleotide.
Expression vectors for transient transfection:
Constructs for transfection were derivatives of pGL3 vector (Promega). The pGL3-Promoter vector was used as control. The hMSH2 luciferase reporter plasmid was kindly provided by Dr K. A. Strait (LDS Hospital, Salt Lake City, UT) and consisted of a 1.88 kb fragment of the upstream promoter region of the hMSH2 gene fused to the luciferase gene on the pGL3-Basic vector (20) . Mutations in the AP-1 sites of the hMSH2 promoter were introduced using the Quick change Mutagenesis kit (Stratagene, La Jolla, CA) with the mutant oligonucleotides designed for the EMSA experiments (612mut and 291mut, compare with`Electrophoretic mobility shift assay', above). A pEGF plasmid (Clontech laboratories, Palo Alto, CA) served as reporter for transfection ef®ciencies by immuno¯uorescence analysis on FACS Calibur¯ow cytometer (Becton Dickinson, USA).
Transient transfection and luciferase activity assays
Conditions for transient transfections of U937 cells were set up using the pEGF vector. Brie¯y, 10 6 cells were electroporated at 1 Hz, 300 V for 10 Q 5 ms (CNRS Cell eletropulsator, Jouan, St Herblain, France) in 100 ml of an isoosmotic solution (10 mM K 2 HPO 4 /KH 2 PO 4 , 1 mM MgCl 2 , 250 mM saccharose) with 10 mg of the Fire¯y luciferase vectors (pGL3 plasmids), and 10 mg of the pEGF plasmid or the Renilla luciferase vectors (pRL-TK, Promega) as internal controls. Electroporated cells were resuspended in 2 ml of 0.5 % serum-containing medium for 24 h incubation at 37°C, 5% CO 2 , and then stimulated by TPA (100 nM) for 6 h. Luciferase assays were performed using the Dual-Luciferase reporter assay system (Promega) that allows sequential determination of the Fire¯y luciferase activity from the hMSH2 construct vectors (pGL3) and the Renilla luciferase activity from the internal control vector (pRL-TK) in the same cell lysate sample. Luminescence was recorded on a TopCount.NXT luminometer (Packard Bioscience Company) for 5 s. All the data are expressed as relative luciferase activity corresponding to the normalisation with the Renilla luciferase values.
RESULTS
Increase of hMSH2 mRNA level through PKC activation
Exposure of U937 cells to TPA stimulates the global PKC activity as a function of time and dose (26) . In a previous article, we reported an induction of hMSH2 expression in response to PKC stimulation (21) . When U937 cells were TPA-treated at various times (3, 6 and 24 h), the amount of hMSH2 protein gradually increased as the incubation time with TPA progressed (Fig. 1A ). The elevation of hMSH2 level paralleled that of mismatch binding activity determined by EMSA experiment (Fig. 1B) .
To clarify the contribution of the PKC stimulation to the upregulation of hMSH2 expression, we evaluated a possible transcriptional activation of hMSH2. This possibility ought to show a concomitant increase of the hMSH2 mRNA with the protein levels in response to PKC induction. In RT±PCR experiments, we observed that the yield of hMSH2 transcripts greatly rose as a consequence of TPA treatment ( Fig. 2A) . The hMSH2 mRNA increase was not associated with changes in the steady-state levels of the HB2 control mRNA (Fig. 2A) .
A semi-quantitative analysis at various ampli®cation cycles speci®ed the difference in the relative ef®ciency of cDNA synthesis from TPA-treated and non-treated cells (Fig. 2B) . The two curves related to the coming out of the PCR products separated at the 15th cycle, and the divergence range from 2-to 5-fold for the later cycles in favour of the TPA-treated cells. Measurements were made within the linear range of ampli®cation. The extent of hMSH2 mRNA was increased bỹ 5-fold when comparing the values after 24 h of incubation time with TPA (Fig. 2C) . From these data, it appears that the induction of hMSH2 mRNA content and protein levels, following TPA treatment, is reached by means of similar extent and kinetics (Figs 1 and 2 ).
Presence of putative binding sites for AP-1 transcriptional activators in MSH2 promoter
One consequence of the activation of PKC is a downstream activation of one of the mitogen-activated protein kinase (MAPK) pathways, and the activation of AP-1 transcriptional factors (27±30). The 5¢ regulatory promoter region of the hMSH2 gene has been characterised (31, 32) , and the sequence analysis shows up the presence of two consensus AP-1 binding sites indicative of a potential regulation of hMSH2 expression. These putative binding sites, also called TRE (TPA response element), are located at ±612 and ±291 from the start of transcription (schematic representation in Fig. 3A) .
To assign an explicit role to the hMSH2 TRE sites, we evaluated the capability of AP-1 binding to these promoter sequences by EMSA. With oligonucleotides containing the ±612 AP-1 binding site of hMSH2 (AP-1/612), a retardation mobility band was detected (Fig. 3B, lane 5) which migrated (Fig. 3B) . The presence in excess of AP-1/612 duplex was able to prevent bandshift of the collagenase AP-1. In contrast, introduction of a mutation into the ±612 sequence rendered it ineffective in the competition experiments (Fig. 3C) . The same results were obtained with alteration in the second hMSH2 AP-1 binding site (AP-1/291, Fig. 3C, lane 4) . Neither one of these two mutated sites, when used as a substrate, showed any signi®cant complex (Fig. 3C, lanes 6 and 7) . These results indicated that the ±612 duplex, and potentially the ±291 duplex, carried the classical TRE sequence target for the AP-1 transcription factors.
We further con®rmed that the protein complex bound to the hMSH2 promoter sequences contained the AP-1 factor c-Jun. Bandshift experiments were realised in the presence of particular c-Jun-antibodies that inhibit the binding of AP-1 complex to its speci®c site. Inclusion of this antibody in the reaction mixture effectively caused a large reduction of the slow migrating band with both the AP-1/Coll and the AP-1/612 duplexes (Fig. 3D) .
Enhancement of the AP-1 binding to the hMSH2 promoter sequence by TPA treatment
We hypothesised that AP-1 might be involved in the regulation of hMSH2 transcription. Treatment with TPA induces a stimulation of AP-1 activity that could be mediated via a PKC signal in different cellular contexts. In this respect, we would expect a better ef®ciency in AP-1 recognition of the promoter for TPA-treated U937 cells than for non-treated controls. We found a faint binding activity on the hMSH2 promoter sequence with U937 cells extracts (Fig. 4) . However, the binding activity appeared really sharper when U937 cells were TPA-treated. The speci®city of recognition was con®rmed by competition with AP-1/Coll duplexes. In parallel, same U937 extracts, treated and not, were assayed for a separate binding activity driven by the Ku heterodimer as a control of the protein extracts quality. As expected, same extent of retardation mobility band was observed for both extracts (Fig. 4, lanes 5 and 6) . These results show that the low AP-1 binding activity present in the U937 cells was enhanced by TPA effect.
Effect of AP-1 on the expression and regulation of hMSH2
The above results were in agreement with the proposition of a cascade of regulation where TPA-stimulated PKC would lead to an activation of AP-1 factors. We then intended to verify the next step of this cascade, i.e. the implication of AP-1 activation in the induction of hMSH2 expression. For this purpose, we used U937 cells that expressed a dominant negative form of c-Jun (dn-Jun) (22) . The dominant negative mutant, lacking the transactivating domain of c-Jun, retains the ability to bind DNA, but is devoid of AP-1 activity. Extracts from dn-Jun cells, either TPA-treated or not, did not show any difference in the hMSH2 expression level (Fig. 5A) , in comparison to the augmentation of the hMSH2 content detected in wild type U937 cells following the same TPA treatment (Fig. 1A) . The presence of a non-functional AP-1 transcription factor in U937 cells abolished the effect of overexpression of hMSH2 induced by TPA.
Beyond that, we checked whether the presence of dominant negative c-Jun would directly affect the transcriptional regulation of hMSH2. Total RNA extracted from TPA-treated dn-Jun cells was analysed in RT±PCR experiments. Whereas the levels of control HB2 mRNA were identical, the number of speci®c hMSH2 transcripts was strictly below that observed in TPA-treated U937 WT cells (Fig. 5B) , and it correlated better with the level of hMSH2 mRNAs from non-treated U937 cells. These data assign to c-Jun a functional role in the regulation of expression of hMSH2 through its activation by TPA.
Functional role of the hMSH2 TRE sequences in vivo
Next, we investigated in vivo the effects of the AP-1 binding sites on the hMSH2 promoter activity. For this purpose, we transiently transfected TPA-treated or untreated U937 cells with luciferase reporter gene whose expression was dependent on the hMSH2 promoter. The constructs contained 1.88 kb of the 5¢ upstream proximal region of the hMSH2 gene (20) , either wild type or speci®cally mutated in the two (±612 and ±291) TRE sites (Fig. 6A) . The base substitutions introduced were the same as those used in band shift assays (Fig. 3C) . When comparing the wild type promoter (wt) and the mutated form (mut), the mutant promoter showed a 2-fold reduction in the luciferase activity (Fig. 6B) . The same observation was made with the two independently single mutants in the ±612 or ±291 boxes (data not shown). These results validated an effect of mutations in the AP-1 sequences on the transactivation of the hMSH2 gene. For further experiments, we generated a deletion of the wild type and mutated promoter to ±950 bp (Dwt and Dmut, Fig. 6A ). This deletion produced a higher decrease (3.4-fold) in the ratio of luciferase activity than the mutation previously examined (compare mut and Dmut in Fig. 6B ). Similarly, a 2-fold reduction of luciferase activity was observed in the presence of curcumin, an inhibitor of c-Jun synthesis (33) , while a higher reduction was detected in presence of the dominant negative c-Jun (Fig. 6B) . The effect obtained with the dominant negative c-Jun mutant (6-fold reduction) was more pronounced than that with the mutated AP-1 sites. This could suggest that mutations in the binding sites did not completely abolish the binding capacity of AP-1 in vivo, in spite of the absence of detectable binding on these mutated sequences in vitro (Fig. 3C) . Finally the cotransfection experiments established that transactivation of hMSH2 promoter is likely to require the intervention of AP-1.
DISCUSSION
Various lines of evidence indicate that DNA repair activities could be regulated at the transcriptional and/or post-transcriptional level leading to phenotypes such as cell resistance or sensitivity to drugs. Among internal or external controls, the activation of PKC has been reported as one of them (34) . Our recent results on MMR activity in myeloid cell lines provided an additional observation on the up-regulation of hMSH2 protein expression after PKC activation by TPA (21) . However, the increased protein expression could lie on various non-exclusive mechanisms. We present here evidence that phorbol-ester stimulation induces a transcriptional upregulation of the hMSH2 gene. By combinations of in vitro and in vivo experiments, we correlated the TPA transactivation of the hMSH2 promoter both to a functional role of the AP-1 binding sites present in the promoter sequence and to the activity of the c-Jun protein.
Following a 24 h-TPA treatment, we found a degree of induction of hMSH2 transcripts that correlated with the 3-to 5-fold increase in protein levels previously detected (21) . Induction of mRNA seemed to precede the augmentation of protein level. RT±PCR analysis revealed a similar extent of mRNA content for 6 and 24 h of TPA stimulation (data not shown), when the kinetic of protein increase is still linear between these two times (Fig. 1) . However, we do not exclude that a post-transcriptional regulation of hMSH2 can superimpose to the transcriptional positive regulation. In this view, PKC phosphorylation of the hMutSa complex has been recently described (13 and H. Hernandez-Pigeon, unpublished observations) leading to an increased protein activity (13) Figure 6 . TPA-enhancement of the hMSH2 promoter is dependent on functional AP-1 binding sites. U937 cells were transiently cotransfected with derivatives of luciferase reporter vectors according to the procedure outlined in Materials and Methods, and afterwards treated or not by TPA (100 nM for 6 h), as indicated. (A) A schematic structure of the constructs in pGL3 plasmid represents the luciferase gene (open box) fused to various forms of the hMSH2 promoter sequence (bold line). A 1.88 kb fragment of the hMSH2 promoter region carrying the AP-1 binding sites, either wild type (wt) or mutated (mut), was inserted upstream of the luciferase gene. Constructs`Dwt' and`Dmut' correspond to the 5¢ truncated sequence of the wild type and mutated promoter region of hMSH2 due to a 930 bp deletion. (B) TPA-stimulated U937 cells were transfected with either wild type or mut hMSH2 promoter, or with the deleted forms of the plasmids.`Wt:cur' means that U937 cells transfected with the wild type hMSH2 promoter were treated with curcumin (50 mM) for 1 h prior to addition of TPA. For`dn-Jun', transfections with wild type hMSH2 promoter were performed on TPA-treated U937 cells containing the dominant negative mutant of c-Jun. Results are shown as the relative luciferase activity reported to that of TPA-treated U937 transfected with the wild type hMSH2 promoter, except for transfections with the Dmut deleted plasmid where the ratio is normalised to transfections with the Dwt plasmid. Data are the means of three independent experiments. Figure 2 . Left, co-ampli®cation of HB2 (HB2) and procaryotic control (control) mRNAs. Right, co-ampli®cation of hMSH2 (hMSH2) and procaryotic control mRNAs.
and/or stability (Hernandez, unpublished observations). An example of dual check of protein expression, i.e. pre-and posttranscriptional control, driven by the PKC, has already been described for another repair gene encoding the alkyl guanine DNA methyl-transferase (MGMT). The MGMT gene transcription is up regulated by PKC depending on AP-1 sequence element (34) . However, in this case, in vivo or in vitro phosphorylation of the protein resulted in a reduced MGMT activity (35) . The signi®cance of the apparent contradictory intervention of the PKC in the regulation of expression/ function of the MGMT is still unclear but could be concerned by the particular mechanism of the MGMT reaction, which is stoichiometric and irreversible.
We produce here two lines of evidence clearly establishing a role of AP-1 in the transactivation of hMSH2 gene. First, we show that the two AP-1 sequences in the promoter region are functional. One (±612) matches exactly the consensus sequence, while the other is slightly degenerated (±291). Both related oligonucleotides were able to bind the AP-1 factor (c-Jun) in band shift experiments. Most importantly, mutations in these sites signi®cantly prevented in vivo the induction of promoter activity associated with phorbol-ester stimulation. Second, we present a set of evidence implicating the participation of c-Jun in the protein complexes formed on the hMSH2 AP-1 sequences. Up regulation of hMSH2 gene seems to depend on a major part on the presence of c-Jun, as demonstrated by experiments carried out using either a dominant negative mutant or speci®c inhibitor (Figs 5 and 6).
We already had an indication that the AP-1 binding sites present in the hMSH2 promoter were potentially functional, even if under speci®c conditions, since these sites were involved in the P53 regulation of hMSH2 associated with UV exposure (19) . The synergism between P53 and c-Jun in response to UV irradiation can be explained on the basis of the presence of binding sites for both P53 and AP-1 in the hMSH2 promoter sequence. However, the type of positive up regulation that we describe here for the hMSH2 transcription is clearly independent of P53, since the U937 cell line used in the study is P53 negative (36 and data not shown). In that case, the P53 independence could be related to the nature of the regulation stimulus, i.e. TPA instead of a DNA damaging agent. Nevertheless, we cannot exclude that the presence of a functional P53 in the U937 cells would even increase the transactivation of hMSH2.
Additional transcriptional regulatory elements could be involved in the TPA-induced mRNA increase. In transient expression assays, when deleting the 5¢ distal sequence of the hMSH2 promoter, we could amplify the difference in relative luciferase activity between wild type and AP-1 mutated promoter (Fig. 6) , despite the fact that a similar deletion has already been described as producing no change in the basal promoter activity (20) . This result suggests that the region corresponding to the deletion could speci®cally perturb the AP-1-dependent transcriptional activation of hMSH2 gene. The hMSH2 promoter displays characteristic features of housekeeping genes (31) , and, in addition to AP-1 binding sites, SP1 (stimulating protein 1), and degenerated NF-kB transcriptional activator sequences are also present in the promoter region. However, it should be noted that data regarding the expression vector carrying a deleted promoter do not constitute a proof for the intervention of other regulatory factors, but could re¯ect the arti®cial nature of this kind of experiment since structure of the promoter region on a DNA plasmid cannot be strictly compared to the endogenous promoter on the chromosome. More accurate analysis of the functionality of the hMSH2 promoter should clarify this point.
The transcriptional regulation of hMSH2 described here may represent a case of regulation ®tting both a particular cell line context and the action of a de®ned inducing agent. Our study concerned leukaemia cells in which the TPA stimulation of PKC is known to play a critical role in signal transduction. Exposure to phorbol-ester is well known to induce the differentiation of immature cells into more mature monocytes/macrophages. However, the conditions of TPA-treatment used in our study do not allow U937 cells to reach the ®nal stage of differentiation as attested by the absence of characteristic features, i.e. cell adherence and monocytic morphology (data not shown). From this point of view, signi®cance of the hMSH2 TPA-induced activation could be related to the shift of transcription associated with the initiation of differentiation, given that hMSH2 would be a candidate for participating in the transcription coupled repair pathway (37) . Alternatively, since the hMSH2 protein has been implicated in the repair of oxidative damage (38, 39) , the AP-1 induction of the hMSH2 gene could then represent a preventive response to the higher ambient O 2 tension to which cells can be exposed from the differentiation pathway.
In summary, our results demonstrate the existence of an AP-1 positive control of the hMSH2 gene and open up the possibility of a regulation operating on other contexts. Interestingly, AP-1 has been suggested to play a critical role in the cellular response to genotoxic agents. This role includes the regulation of genetic programs associated with a process fundamental for cellular protection and survival, such as DNA repair. Indeed AP-1 target genes exist among known repair genes, ERCC1 and MGMT (34, 40) . And for both of them, AP-1 induced transcription arises in response to genotoxic stress mediated by cisplatin (40) , or alkylating agents (34) . Given this background, we have undertaken studies aimed at determining potential extracellular signals, including genotoxic agents, implicated in the modulation of hMSH2 gene expression, and at examining whether other MMR genes are AP-1 responsive genes.
